Gravar-mail: AT-27 CHALLENGES OF RETROSPECTIVELY DETERMINING THE EQUIVALENCE OF PCV VERSUS TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED 1p/19q CO-DELETED ANAPLASTIC OLIGODENDROGLIOMAS